טיויקיי 50 מ"ג - Tivicay 50 mg
× ×ª×× × ×ª×¨×פ×
×××¨×©× 
| ××× ×× ×× × ×ספ×× | |||||||
|---|---|---|---|---|---|---|---|
| ק×××¦× ×¤×¨×ק×××××ת (ATC4) | J05AJ03 Integrase inhibitors | ||||||
| ×ר××× ×¤×¢×× (ATC5) | Â
| ||||||
| צ×רת ××ª× | פ××× - PER OS | ||||||
| צ×רת ××× ×× | ×××××ת ×צ×פ×ת פ×××, FILM COATED TABLETS ××× ×עת ××× ×× ×תר ×× ×רע×× ×ש ××××× ×ת ×תר××¤× ××ת×× ×××× ×× ××××××¥ ××¤× ×©××פ××¢ ××¢××× ×צר×× | ||||||
| ×ת×××× | Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children above 6 years of age.
| ||||||
| |||||||
| ×¢××× ×ר××¤× ××××ר×ת ××¢××× |
 Â
| ||||||
| ×¢××× ×צר×× |  |
|---|
| ער××× ××××ק×רפ××× | ער××× ×§×©×ר×× ××××ק×רפ××× |
|---|---|
| ××××ק×× 50 ×"× ××××ר ××©×¨× ××ר×××ת
××××ק×× 50 ×"× ××××ר ××©×¨× ××ר×××ת |
| ××פ×ש ×××ר×× | ×××ר×× ×-PubMed |
|---|---|
| ××××¢ ×רשת | RxList WebMD Drugs.com |
| ×©× ××¦×¨× | GLAXO WELLCOME SA, SPAIN |
| ×©× ××¢× ×ר×ש×× | GLAXO SMITH KLINE (ISRAEL) LTD |
| ר×ש××× | ת×ר×× ××ש×: 08/2014. ר×ש××× ×ת×ר××: 08/2014 |
| ת×ר×× ×¢×××× ××ר×× | 15/05/19 |
ת××× ×ª ×ר×××
××××¢ × ×סף ×ר×פ×××
×צפ××× ×××××¢ ××ר×× ×ר×פ××× ×ש ××××× ×¡ ××ש××× ×. ×× ××× × ×¨×©×× ××× ×¡ ××רש×× ×ר×פ××× ××× ×©× ×קצ××¢×ת רפ×××××.
סר××× ××
×צפ××× ×××××¢ ××ר×× ×ר×פ××× ×ש ××××× ×¡ ××ש××× ×. ×× ××× × ×¨×©×× ××× ×¡ ××רש×× ×ר×פ××× ××× ×©× ×קצ××¢×ת רפ×××××.
×צ×ת ××צר
×צפ××× ×××××¢ ××ר×× ×ר×פ××× ×ש ××××× ×¡ ××ש××× ×. ×× ××× × ×¨×©×× ××× ×¡ ××רש×× ×ר×פ××× ××× ×©× ×קצ××¢×ת רפ×××××.
×צ×ת 1 - Tivicay Summary Slide Deck
×צ×ת 2 - SINGLE STUDY - Tivicay vs Atripla in Treatment Naïve Participants
×צ×ת 3 - SPRING STUDY - Tivicay vs Raltegravir in Treatment Naïve Participants
×צ×ת 4 - FLAMINGO STUDY - Tivicay vs Darunavir/Ritonavir in Treatment Naïve Participants
×צ×ת 5 - SAILING STUDY - Tivicay vs Raltegravir in Treatment Experienced Participants
×צ×ת 6 - VIKING STUDY - Tivicay in Antiretroviral Experienced Patients With Antiretroviral Resistance
×××ר××
×צפ××× ×××××¢ ××ר×× ×ר×פ××× ×ש ××××× ×¡ ××ש××× ×. ×× ××× × ×¨×©×× ××× ×¡ ××רש×× ×ר×פ××× ××× ×©× ×קצ××¢×ת רפ×××××.
- al Experienced Patients With Raltegravir and or Elvitegravir Resistant HIV-1 24-Week Results of the Phase III VIKING-3 Study
- Dolutegravir vs twice-daily Raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study) 48 week results
- Dolutegravir vs twice-daily Raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study) 96 week results
- ravir vs Raltegravir in antiretroviral experienced, integrase inhibitor naive adults with HIV week 48 results- SAILING study
- ritonavir in antiretroviral naive adults with HIV1 infection (FLAMINGO) 48 week results from the randomized open-label phase
השינוי האחרון נעשה בֹ־17 ביוני 2025 ב־15:19